Dr. Sereti on Addressing an Unmet Need With NOV202/Olaparib in BRCA1/2-Mutated Prostate Cancer

Evangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.

Evangelia Sereti, MSc, PhD, a postdoctoral fellow at Urological Cancer, Malmö, Division of Translational Cancer Research, Lund University Cancer Centre, discusses the unmet need addressed with the addition of NOV202 to olaparib (Lynparza) in BRCA1/2-mutated prostate cancer.

Preclinical findings, which were presented during the 2021 EAU Congress, aimed to evaluate whether NOV202, a vascular-disrupting agent, could increase the anticancer efficacy of the PARP inhibitor olaparib in prostate cancer–based xerograph mouse models with BRCA1/2 mutations, Sereti says.

This research addresses an urgent clinical need, which is to develop novel, combinational therapeutic strategies that can improve the efficacy observed with single-agent PARP inhibitors, prevent or overcome resistance to PARP inhibitors, and expand the population that may benefit from treatment with PARP inhibitors, Sereti concludes.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Linda Fleisher, PhD, MPH
David Gerber, MD
Related Content